Life Sciences
Bill Gates-backed Triangle startup targeting Alzheimer’s treatment raises $6M
An RTP based drug development firm backed by a Bill Gates-linked foundation has raised more than $6 million as it continues to develop an Alzheimer’s treatment.
The…
RESEARCH TRIANGLE PARK – An RTP based drug development firm backed by a Bill Gates-linked foundation has raised more than $6 million as it continues to develop an Alzheimer’s treatment.
T3D Therapeutics disclosed the new funding in an SEC filing. The company, launched in 2013, says it has embraced a “transformational approach to treating Alzheimer’s and other neurodegenerative diseases.”
In 2020 the company received a $740,000 grant from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program.
Its lead compound is currently in a Phase 2 clinical trial.
The company received funding from 23 investors, according to the filing. It hopes to raise $7.5 million.
T3D raised $15 million in 2019 and $6 million in 2018.
Bill Gates, Alzheimer’s Association provide $740K grant to RTP startup
The post Bill Gates-backed Triangle startup targeting Alzheimer’s treatment raises $6M first appeared on WRAL TechWire.
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….
